{"entity":{"id":"nct06574347","kind":"trial","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","aka":["KYLIN-2"],"tldr":"A phase 2 trial of Vebreltinib, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.","summary":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. is a phase 2 interventional study registered as NCT06574347 by Avistone Biotechnology Co., Ltd., with 120 participants planned, started 2024-08-07 and due to reach its primary completion in 2026-10-31. Interventions recorded: Vebreltinib, Osimertinib, PLB1004. Conditions listed: Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06574347","url":"https://clinicaltrials.gov/study/NCT06574347"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","met-altered-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["vebreltinib","osimertinib"],"companies":["avistone-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06574347","phase":"2","setting":"A Phase II Study of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer.","sponsor":"Avistone Biotechnology Co., Ltd.","started":"2024-08-07","startedType":"actual","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06574347/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}],"company":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/"}]}}